Objectives: Prostate specific antigen (PSA) is the most commonly used markerfor prostate cancer. PSA-based screening has reduced disease-specific mortality.However, PSA is not specific for prostate cancer, but is specific for prostate tissue andincreases in benign conditions.Material and Methods: In our study, 63 patients with PSA values of 1.5 ng / ml or lesswere evaluated retrospectively with 636 patients who underwent prostate samplingbecause of the suspicion of prostate cancer.Results: In our study, 34.9% prostate cancer and 4.1% ASAP were detected below1.5 ng / ml of PSA. Our results suggest that a significant number of cancers weredetected below 1.5 ng / ml of PSA.Conclusion: A significant number of prostate cancers are found below 1.5 ng / mlPSA. The lack of a PSA value that we can say without prostate cancer leads to theneed for a low cost and reliable marker.